You are here: Industry Insights > vedolizumab

News List

Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions drugs
September 26, 2019
In moderate-to-severe ulcerative colitis, vedolizumab is superior to adalimumab for achieving clinical remission and endoscopic improvement ...
FDA Accepts Takeda’s BLA for a Subcutaneous Formulation of Vedolizumab americanpharmaceuticalreview
May 10, 2019
FDA Accepts Takeda’s BLA for a Subcutaneous Formulation of Vedolizumab.
Takeda’s Entyvio outperforms AbbVie’s Humira in GI trial March 12, 2019
Takeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – AbbVie’s Humira – in severely active ulcerative colitis.
In a first ever head-to-head biologic clinical study in Ulcerative Colitis Takeda's Entyvio demonstrates superior results compared to Humira biospectrumasia
March 11, 2019
Vedolizumab superior to adalimumab in achieving clinical remission and mucosal healing at week 52 in patients with moderately to severely active ulcerative colitis
New Phase 3 Data Shows Vedolizumab Met Primary Endpoint americanpharmaceuticalreview
July 24, 2018
Takeda announced top-line results from the VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerati
Sub-cutaneous form of Entyvio hits PhIII safety, efficacy goals pharmatimes
July 20, 2018
Takeda says it has late-stage trial results showing the benefit of an investigational subcutaneous formulation of Entyvio to patients with ulcerative colitis.